View Older Stories View More Recent Stories

Feb 4, 2026 07:08AM H.C. Wainwright Reiterates Buy Rating on Exelixis (EXEL)
Feb 2, 2026 08:03AM FDA accepts Exelixis drug application for colorectal cancer treatment
Jan 27, 2026 07:06AM Exelixis (EXEL) PT Raised to $52 at H.C. Wainwright
Jan 14, 2026 08:56AM Exelixis (EXEL) PT Raised to $51 at Truist Securities
Jan 14, 2026 04:48AM Exelixis (EXEL) Reiterated at Market Outperform by Citizens
Jan 12, 2026 08:28AM Exelixis (EXEL) Reiterated at Hold by Stifel: Earlier Pipeline 'a Showme Story'
Jan 12, 2026 04:05AM Exelixis reports $2.123 billion preliminary 2025 revenues, guides higher for 2026
Jan 8, 2026 03:36AM Morgan Stanley Downgrades Exelixis (EXEL) to Equalweight
Jan 5, 2026 06:19AM BofA Securities Downgrades Exelixis (EXEL) to Underperform
Dec 18, 2025 04:29AM Exelixis (EXEL) Has Multiple Upcoming Milestones for Zanzalintinib - Citizens
Dec 11, 2025 07:42AM Exelixis' (EXEL) Zanzalintinib Centerpiece of Near-term Strategy - Stifel
Nov 17, 2025 04:12PM Wolfe Research Starts Exelixis (EXEL) at Peerperform
Nov 5, 2025 01:55AM Oppenheimer Reiterates Perform Rating on Exelixis (EXEL)
Nov 4, 2025 04:27PM Exelixis authorizes additional $750 million stock repurchase program
Nov 4, 2025 04:17PM Exelixis (EXEL) Tops Q3 EPS by 9c, provides guidance
Oct 21, 2025 05:33AM Exelixis (EXEL) PT Lowered to $30 at Wells Fargo
Oct 21, 2025 04:09AM Citizens Reiterates Exelixis (EXEL) at Market Outperform on STELLAR-303 Franchise Potential
Oct 20, 2025 08:27AM Truist on Exelixis (EXEL): 'STELLAR-303 Unlikely To Drive Broad Adoption'
Oct 14, 2025 07:29AM Truist Securities Reiterates Buy Rating on Exelixis (EXEL)
Oct 7, 2025 03:02PM Exelixis (EXEL) call put ratio 1 call to 19 puts with a focus on 4K contracts of November 31 puts
Sep 22, 2025 09:33AM Exelixis (EXEL) PT Lowered to $35 at UBS, Upcoming Zanza Data Expected to Disappoint
Sep 19, 2025 04:06AM Barclays Assumes Exelixis (EXEL) at Equalweight
Sep 17, 2025 02:27AM Goldman Sachs Starts Exelixis (EXEL) at Buy
Aug 12, 2025 06:40AM Exelixis (EXEL) PT Lowered to $46 at H.C. Wainwright
Jul 29, 2025 09:20AM Exelixis (EXEL) PT Lowered to $45 at RBC Capital
Jul 29, 2025 09:02AM Exelixis (EXEL) PT Raised to $41 at Stifel
Jul 29, 2025 08:46AM Exelixis (EXEL) PT Lowered to $49 at Truist Securities
Jul 29, 2025 04:57AM Citizens JMP Reiterates Market Outperform Rating on Exelixis (EXEL)
Jul 28, 2025 04:57PM After-hours movers: Western Union, Whirlpool, Exelixis, and more
Jul 28, 2025 04:09PM Exelixis (EXEL) Tops Q2 EPS by 11c, provides guidance
Jul 24, 2025 05:04PM Exelixis partner Ipsen gets EU approval for neuroendocrine tumor treatment
Jul 24, 2025 04:31AM Citizens JMP Reiterates Market Outperform Rating on Exelixis (EXEL)
Jul 23, 2025 02:43PM Exelixis (EXEL) call put ratio160 calls to 1 put with a focus on August 45 and 50 calls
Jul 15, 2025 09:12AM Exelixis (EXEL) PT Raised to $56 at Truist Securities
Jun 30, 2025 06:48AM Exelixis (EXEL) PT Raised to $53 at H.C. Wainwright
Jun 23, 2025 10:32AM UBS Reiterates Neutral Rating on Exelixis (EXEL)
Jun 23, 2025 10:09AM Stifel Reiterates Hold Rating on Exelixis (EXEL)
Jun 23, 2025 10:09AM William Blair Reiterates Outperform Rating on Exelixis (EXEL), 'First pivotal success from the zanzalintinib program'
Jun 23, 2025 09:20AM Exelixis (EXEL) PT Raised to $55 at Truist Following 'A Nice First Pivotal Win'
Jun 23, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Exelixis (EXEL)
Jun 23, 2025 04:47AM Exelixis (EXEL) PT Raised to $50 at Citizens JMP
Jun 12, 2025 08:12AM H.C. Wainwright Reiterates Buy Rating on Exelixis (EXEL)
Jun 5, 2025 05:26AM Exelixis (EXEL) PT Raised to $46 at BofA Securities
Jun 3, 2025 01:02PM Stifel Reiterates Hold Rating on Exelixis (EXEL)
Jun 3, 2025 04:22AM Citizens JMP Reiterates Market Outperform Rating on Exelixis (EXEL)
May 30, 2025 05:01AM Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
May 22, 2025 05:18PM Exelixis (EXEL) announces results from Phase1b/2 trial evaluating Zanzalintinib
May 14, 2025 09:21AM Exelixis (EXEL) PT Raised to $38 at Stifel
May 14, 2025 09:17AM Exelixis (EXEL) PT Raised to $44 at TD Cowen Following 'Solid Q1 Beat & Guidance Raise'
May 14, 2025 08:58AM RBC Capital on Exelixis (EXEL): 'Strong Quarter with Cabo's Strength Shines'
View More Recent Stories View Older Stories